The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva® Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy, being held May 26 – 30 in London. The LuViva, a non-invasive device used to detect cervical disease instantly at the point of care, is a product of Guided Therapeutics, Inc. (GTHP) (GTHP).
The title of the abstract is “LuViva Cervical Scan as a Triage Test to Reduce Unnecessary Colposcopy and Biopsy.” The study was conducted by Dr. James Bentley, who is also Professor and Division Head of Gynecology Oncology at Dalhousie University School of Medicine in Halifax, Nova Scotia and Dr. Richard Zane at the Atlanta Women’s Research Institute in Atlanta, Georgia.
“We believe that the results of this new clinical study, to be presented to the leading cervical cancer experts from around the world, will further validate LuViva’s future role in improving the diagnosis of cervical cancer in women across the globe,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “There is a critical unmet need in gynecology for a product like LuViva that provides immediate results at the point of care, eliminates unnecessary procedures and finds disease that can be missed by the standard of care. We believe that the opportunity for LuViva, particularly in international markets, is tremendous and we plan on capturing that opportunity.”
“We also want to thank Dr. Bentley and Dr. Zane for their hard work and for recognizing the potential of LuViva at an early stage,” said Mr. Cartwright. “Once published, the study will be used in our approved international markets to support our distributors and LuViva’s expanding product launch.”
About the IFCPC
The International Federation for Cervical Pathology and Colposcopy represents 37 National Pathology and Colposcopy Societies from around the world. The IFCPC’s 15th World Congress will bring together leading scientists, public health experts and policy-makers to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. For more information visit, http://ifcpc2014.com.
About LuViva® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (GTHP) (GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva®Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and subsequent quarterly reports.
- Health Care Industry
- James Bentley
- cervical cancer
Bill Wells, 770-242-8723
Alison Ziegler, 212-554-5469